OmniAb Investor Conference Presentation Deck
Teclistamab
APPROVED BISPECIFIC ANTIBODY FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
●
A fully humanized IgG4, T-cell redirecting, bispecific antibody targeting both BCMA (B-cell
maturation antigen) and CD3
- Discovered in part with the OmniAb platform technology (anti-BMCA portion)
In December 2021 and January 2022, Janssen submitted a BLA to the FDA and a MAA to the
EMA, respectively, for approval in the treatment of relapsed or refractory multiple myeloma
●
●
●
-
Janssen
Granted Orphan Drug Designation and Breakthrough Therapy Designation by FDA, and Orphan Drug
Designation and a PRIority MEdicines (PRIME) designation by EMA
At ASCO 2022, Janssen presented updated efficacy and safety results from Phase 1/2 MajesTEC-1
study, demonstrating continued deep and durable responses in the treatment of RRMM; results
from MajesTEC-1 were also published in The New England Journal of Medicine
Janssen received conditional marketing authorization (CMA) by the European Commission in
August of 2022 and accelerated approval by the US FDA in October of 2022
Under the terms of the licensing agreement with an affiliate of Janssen, OmniAb, Inc. is eligible to
receive a $25 million milestone payment upon first commercial sale in US and a $10 million milestone
payment upon first commercial sale in Europe(1)
(1) United Kingdom, Italy, Germany, France or Spain
43
OmniAbView entire presentation